Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and IMbrave150. We conducted indirect comparisons of therapies evaluated for first-line HCC treatment. Summary: We conducted a sy...

Full description

Bibliographic Details
Main Authors: Arndt Vogel, Lorenza Rimassa, Hui-Chan Sun, Ghassan K. Abou-Alfa, Anthony El-Khoueiry, David J. Pinato, Javier Sanchez Alvarez, Monica Daigl, Panos Orfanos, Michael Leibfried, Marie-Hélène Blanchet Zumofen, Vincent E. Gaillard, Philippe Merle
Format: Article
Language:English
Published: Karger Publishers 2021-05-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
cancer immunotherapy
atezolizumab
meta-analysis
Online Access:https://www.karger.com/Article/FullText/515302

Internet

https://www.karger.com/Article/FullText/515302

Similar Items